Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck - Xconomy

Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck  Xconomy

Bristol-Myers Squibb (NYSE: ]) this afternoon revealed yet another setback for its cancer immunotherapy nivolumab (Opdivo) in lung cancer, boosting the.